Diasmoke 2.0 is a CoEHAR research project that aims to assess health improvements and changes in cardiovascular risk factors in smokers with Type 2 Diabetes who switch to combustion-free nicotine

A recent randomized controlled trial of varenicline (Chantix) combined with psychological support has significantly increased the chance of quitting smoking for 300 smokers with type 2 diabetes mellitus LINK TO

LINK TO THE STUDY  Quitting smoking can reduce cardiovascular and kidney failure risks. However, it can lead to side effects such as weight gain. A scoping review conducted by a

“This agreement means capitalizing the scientific potential of our universities, investing in young people and their future” said prof. Emil Ceban. Catania,17th November 2021. Academic cooperation between the Center of

With the first subjects enrolled, the Diasmoke project has entered the recruitment phase. The main goal of the project by CoEHAR is to determine whether smokers with diabetes mellitus- who

On Monday 22 March from 9.30 to 17.00 CET, on the Zoom platform, the CoEHAR (Center of Excellence for the acceleration of Harm Reduction) will hold the kick off meeting